SetPoint Medical today announced FDA Investigational Device Exemption approval to study its proprietary neuroimmune modulation platform for people with relapsing-remitting multiple sclerosis.
AtriCure (Nasdaq: ATRC)+
announced that it received CE mark for the EnCompass clamp for cardiac tissue ablation procedures.
BioIntelliSense announced today that it received FDA clearance for its rechargeable BioButton multi-patient wearable and BioDashboard system.
The 3D capabilities are part of Siemens’ first completely redesigned mammography platform in over a decade.
Qnovia announced that the FDA cleared its investigational new drug (IND) application for the RespiRx smoking cessation inhaler (QN-01).